News >

Frontline Maintenance Olaparib Approved in Europe for Ovarian Cancer

Gina Columbus @ginacolumbusonc
Published: Tuesday, Jun 18, 2019

Dave Fredrickson

Dave Fredrickson

The European Commission has approved olaparib (Lynparza) as a single agent for the maintenance treatment of adult patients with advanced BRCA1/2-mutated germline and/or somatic high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response (PR) following first-line platinum-based chemotherapy.1

The approval is based on findings from the double-blind, phase III SOLO-1 trial, in which maintenance olaparib led to a 70% reduction in the risk of disease progression or death compared with placebo in patients with BRCA-mutant advanced ovarian cancer after completing frontline platinum-based chemotherapy (HR, 0.30; 95% CI, 0.23-0.41; P <.001).2,3

The FDA approved olaparib for this indication in December 2018.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication